Traci McCarty | VP, IR |
J.J. Bienaime | Chairman & CEO |
Jeffrey Ajer | EVP & Chief Commercial Officer |
Henry Fuchs | President, Worldwide Research & Development |
Brian Mueller | EVP, Finance & CFO |
Philip Nadeau | Cowen and Company |
Salveen Richter | Goldman Sachs |
Jessica Fye | JPMorgan Chase & Co. |
Srikripa Devarakonda | Truist Securities |
Paul Matteis | Stifel, Nicolaus & Company |
Robert Finke | Guggenheim Securities |
Joseph Schwartz | SVB Securities |
Lachlan Brown | William Blair & Company |
Gena Wang | Barclays Bank |
Joel Beatty | Robert W. Baird & Co. |
Geoffrey Meacham | Bank of America Merrill Lynch |
Gena Wang | Barclays Bank |
Christopher Raymond | Piper Sandler & Co. |
Olivia Brayer | Cantor Fitzgerald |
Luca Issi | RBC Capital Markets |
Matthew Harrison | Morgan Stanley |
Welcome to the BioMarin Third Quarter 2022 Financial Results Conference Call. Hosting the conference call today from BioMarin is Traci McCarty, Group Vice President of Investor Relations. Please go ahead, Traci.
Thank you, Ross, and thank you all for joining us today. To remind you, this nonconfidential presentation contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc.